Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation.
Nelli BejanyanJohn RogosheskeQing CaoAleksandr LazaryanShernan HoltanCelalettin UstunPamala JacobsonMargaret MacMillanDaniel J WeisdorfJohn WagnerMukta AroraClaudio G BrunsteinPublished in: European journal of haematology (2020)
Weight-based MMF dose had no significant impact on engraftment, chronic GVHD, or survival. These data suggest that higher weight-based MMF dose reduces the risk of acute GVHD at the expense of increased relapse and supports conducting prospective studies to optimize MMF dosing after HCT.
Keyphrases
- liver failure
- body mass index
- weight loss
- allogeneic hematopoietic stem cell transplantation
- free survival
- physical activity
- weight gain
- respiratory failure
- drug induced
- aortic dissection
- body weight
- stem cell transplantation
- bone marrow
- hematopoietic stem cell
- electronic health record
- acute lymphoblastic leukemia
- big data
- cell death
- low dose
- machine learning
- cell proliferation
- signaling pathway
- artificial intelligence
- cell cycle arrest